Excellent
Fully Aligned
Patient Risk:
Low
Summary
The claims correctly identify the marketed brand name Gazyva for obinutuzumab, which is consistent with the provided label context (GAZYVA/obinutuzumab) and contains no contradictions.
Category Scores
Accurate Statements
Obinutuzumab is marketed under the brand name Gazyva.
The provided label excerpts and references are explicitly for GAZYVA (obinutuzumab), indicating the brand name corresponds to obinutuzumab.
The key marketed brand name for obinutuzumab is Gazyva.
Same basis: the labeling provided is for GAZYVA (obinutuzumab), supporting the brand-name linkage.
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The claims are limited to brand-name identification and do not make safety, dosing, or clinical risk statements.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Fully Aligned
Primary Issue
Suggested Improvement